The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical studies without systematic review methodology.
PubMed 34444763 · doi:10.3390/nu13082603
What was done
The authors conducted a narrative review summarizing preclinical and clinical evidence on the potential anti-calcific roles of specific nutraceuticals—including magnesium, zinc, iron, vitamin K, and phytate—for the prevention and treatment of cardiovascular calcification.
What was found
The abstract provides no quantitative metrics or effect sizes. It qualitatively reports that evaluated nutraceuticals (magnesium, zinc, iron, vitamin K, and phytate) show potential anti-calcific effects against the progression of vascular calcification in preclinical and clinical settings, though optimal clinical dosages have not yet been established.
Why it matters
Cardiovascular calcification lacks approved pharmacological treatments, making the evaluation of accessible dietary compounds a potential cost-effective strategy for prevention in high-risk populations.
Limits
This is a narrative review rather than a systematic review or meta-analysis. The abstract provides no specific quantitative outcomes or sample sizes, notes that optimal therapeutic dosages remain unknown, and emphasizes that large-scale interventional clinical trials are still required to confirm efficacy.
Cited by
- context Magnesium is involved in allowing vitamin K2 to work to prevent calcium deposition in soft tissues.